http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-086852-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09cf654421401ec2aea00d0a5bfa001e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ae122432078c5b8728a897b4ed1d00d |
| publicationDate | 2014-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-086852-A1 |
| titleOfInvention | 1,1-DIOXIDE COMPOUNDS OF [1,2,4] TIADIAZINE TO REDUCE SERIOUS URIC ACID |
| abstract | The present discloses [1,2,4] thiadiazine 1,1-dioxide compounds and their pharmaceutically acceptable salts, which are useful for the reduction of serum uric acid in a patient in need thereof comprising administration to the patient of a Therapeutically or preventively effective amount of a [1,2,4] thiadiazine 1,1-dioxide compound. Claim 1: A method of reducing serum uric acid in a patient comprising administering to the patient a therapeutically effective amount of a compound of the formula (1) wherein ring B is a residue of formula (2) or (3); A is the rest of formula (4) or (5); Z is - (CR11R12) n-; Y is - (CR13R14) m-; n is 1 or 2; m is 2 or 3; R1 is H, -NH2 or - (CH2) q-NH-S (O) 2CH3, where q is 0 or 1; R2 is C1-6 alkyl, C3-6 cycloalkyl, aryl or - (CH2) -R15, where R15 is a moiety of formula (6), wherein R16, R17, R18, R19 and R20 are, independently, H, C1-6 alkyl, hydroxy or halo; R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are, independently, H or C1-6 alkyl; wherein each alkyl, cycloalkyl or aryl are optionally substituted with one or more alkyl, hydroxyl or halo substituents; or one of its therapeutically acceptable salts, hydrates, solvates, tautomers or stereoisomers. |
| priorityDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.